The advent of high-throughput "-omic" technologies over the past 2 decades has driven a vast expansion in the search for clinical biomarkers, as manifested by the plethora of publications on biomarker discovery (over 8600) listed on PubMed since 2000. Unfortunately, the same time period has seen a relative dearth of clinically validated biomarkers that have received Food and Drug Administration clearance; only 10 new cancer biomarkers have been cleared by the Food and Drug Administration in the same time period (1 ) .
Although it is technically fairly straightforward to identify differentially expressed genes and gene products that are statistically associated with various clinical conditions, it is much more difficult to convert statistical associations into clinically useful biomarkers that meet the required performance characteristics of specificity, sensitivity, and reliability that are required for most clinical applications. This problem is particularly acute in the case of biomarkers for early detection of cancer, given the relatively low prevalence of many cancers and the substantial consequences of both falsenegative and false-positive results. Early detection of ovarian cancer is a particularly illustrative example. The discrepancy in clinical outcome between stage I/II ovarian cancer and stage III/IV is compelling, with Ͼ85% survival for stage I ovarian cancer, but Ͻ20% survival at 5 years for stage III/IV. However, almost 85% of all ovarian cancer patients are diagnosed at stage III/IV (2, 3 ) . With the prevalence of ovarian cancer being only about 1 in 10 000, biomarkers for its early detection must demonstrate specificity Ͼ99% at sensitivities Ͼ80% (4 ).
Much has been written about the required characteristics of clinically useful biomarkers [see for example (4 ) ] and about the quality control checks that need to be in place to enhance the likely utility of candidate biomarkers (5, 6 ) . A consensus pipeline has emerged from these discussions, consisting of a staged approach distinguishing between discovery, verification, preclinical validation, and clinical validation (7, 8 ) . A key element of this staged approach to biomarker development is the adoption of stage-specific criteria for experimental design and quality assurance that become progressively more stringent until full Food and Drug Administration criteria for clinical trials are met.
The first step in biomarker discovery is usually a series of preclinical exploratory studies, which can be either hypothesis-driven explorations of functionally significant cellular processes for surrogate markers or hypothesis-neutral, predominantly statistical assessments of large data sets for statistically significant associations. However, regardless of the method used to devise a list of candidate biomarkers, the next required process is the development and validation of a clinical assay. It is at this stage that several rigorous filters are applied to focus the search on the most promising candidates. Many of the filters are statistical in nature, assessing the relative performance of candidate markers on relatively small, "convenience" sample sets that are themselves subject to experimental bias and confounding factors. Thus, an imperative next step is the reproduction of the original result on a completely independent sample set, which is presumed to have an independent set of potential confounders (8 ) . However, an essential step in this transition is the development of an assay system that can be scaled up to sample sets sufficiently large for statistical validity, as well as locking down an assay format that is robust, reproducible, and accurate.
The traditional approach to evolving new assays for protein biomarkers has been the development of immunoassays (most frequently, sandwich ELISAs). Although ELISAs have many desirable characteristics for clinical use, it is blatantly obvious that any ELISA is only as good as the component antibodies. In-house development of clinical-grade, ELISA-qualified monoclonal antibody pairs can take months to years and an investment of tens of thousands of dollars. Multiply this investment by the number of candidate biomarkers that fail to validate successfully in phases 2 or 3, and a biomarker development program funded by individual research grants can easily go broke. When a commercially produced ELISA kit is available for the antigen of interest, the temptation to use those reagents, rather than developing your own, is highly compelling. This utilization of commercial reagents was the pathway taken by Prassas et al. (9 ) , as described in this issue of Clinical Chemistry. In this study, the preclinical exploratory stage used data-mining of gene expression and proteomic data to identify secreted and/or membrane proteins that were pancreas specific (10 ) . Of these candidates, CUB and zona pelucida-like domain-containing protein 1 precursor (CUZD1) was subjected to further verification studies by using a commercial CUZD1 ELISA kit purchased from USCN Life Science. The initial results were highly promising (10 ) . However, before conducting further preclinical validation studies, the research group made the intelligent decision to rigorously characterize the performance characteristics of the commercial CUZD1 ELISA kit. As documented with great care in this issue, the research team determined that the ELISA kit they had been using did not identify CUZD1, but identified MUC16 (CA125), a previously well-qualified biomarker for ovarian cancer that is also highly expressed in pancreatic and lung cancers (11 ) .
The true cost of using this convenient commercially available kit goes beyond the research dollars spent [$500 000 in Prassas et al. (9 )], but includes the negative impact on young scientists who devoted several years of their careers to pursuing a false lead. This example is not the first instance of misleading results stemming from poorly characterized commercial antibodies; see also Gutierrez et al. (12 ) . What is to be learned from this incident? It is easy to point fingers at a single vendor (the same company in both of these cases) and avoid their products in the future, but the real issue goes beyond that. This is a sobering reminder that all good biochemistry requires orthogonal verification at some point in the process, and it is better sooner than later. The work flow described in Prassas et al. (9 ) provides an excellent template.
A key orthogonal method used by Prassas et al. included the use of mass spectrometry to confirm the identity of the protein(s) recognized by the ELISA antibodies in Western blots. The mass spectrometry results provided key evidence that CUZD1 was not the target of the ELISA and additionally suggested putative targets for further investigation. Targeted mass spectrometry methods, in which only specific precursor ions are analyzed, have the advantage of an internal validation step, in that both precursor and product ions are measured accurately and high levels of precision are achieved (13 ) . Recent technical advances in both mass spectrometry platforms and in work flows for targeted mass spectrometry analyses, enabling detection and quantification at less than 1 ng/mL (13, 14 ) , suggest that investigators might soon be able to proceed through the initial verification and preclinical validation phases without the requirement for antibody development, thus focusing antibody development only on those targets worth pursuing and additionally increasing the return on investment for highly rigorous antibody development efforts. 
